Remus Pharmaceuticals Limited IPO Detail
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
- APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.
- Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.
The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.
As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.
Company Promoters
Mr. Arpit Deepakkumar Shah, Ms. Roma Vinodbhai Shah, Mr. Swapnil Jatinbhai Shah and Mrs. Anar Swapnil ShahIPO Details
| IPO Opening Date | May 17, 2023 |
| IPO Closing Date | May 19, 2023 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹10 per equity share |
| IPO Price | ₹1150 - 1229 per equity share |
| Market Lot | 100 Shares |
| Min Order Quantity | 100 Shares |
| Listing At | NSE SME |
| Issue Size | ₹47.69 Cr |
| Fresh Issue | ₹47.69 Cr |
| Offer for Sale | - |
| Retail Portion | 35% |
IPO Subscription (Bidding Detail)
| AS On | QIB | SHNI | BHNI | NII | RII | TOTAL |
|---|---|---|---|---|---|---|
| Day 1 | 0.00x | - | - | 2.85x | 2.85x | 1.43x |
| Day 2 | 1.48x | - | - | 12.25x | 10.93x | 6.41x |
| Day 3 | 10.75x | - | - | 229.31x | 49.81x | 57.21x |
IPO Tentative Timetable
The Remus Pharmaceuticals Limited IPO open date is May 17, 2023, and the close date is May 19, 2023. The issue may list on May 29, 2023.
| IPO Open Date | May 17, 2023 |
| IPO Close Date | May 19, 2023 |
| Basis of Allotment Date | May 24, 2023 |
| Initiation of Refunds | May 25, 2023 |
| Credit of Shares to Demat Account | May 26, 2023 |
| IPO Listing Date | May 29, 2023 |
IPO Lot Size
The Remus Pharmaceuticals Limited IPO market lot size is 100 shares. A retail-individual investor can apply for up to 1 lots (100 shares or ₹122900).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 100 | ₹122900 |
| Maximum | 1 | 100 | ₹122900 |
IPO Promoter Holding
| Pre Issue Share Holding | 92.82% |
| Post Issue Share Holding |
Company Financials:
For the year/period ended (₹ in Lakhs)
| Financial Year | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-20 | 530.36 | 1,276.89 | 81.16 |
| 31-Mar-21 | 1,104.96 | 1,922.45 | 102.58 |
| 31-Mar-22 | 1,590.93 | 2,543.71 | 338.57 |
| 31-Dec-22 | 3,352.96 | 3,361.20 | 643.90 |
Objects of the Issue:
The Issue Proceeds from the Fresh Issue will be utilized towards the following objects:
- To Meet Working Capital Requirements
- Funding investments for acquisitions and general corporate purposes
- To meet Public Issue Expenses
Remus Pharmaceuticals Limited IPO Registrar:
Link Intime India Private Ltd
Remus Pharmaceuticals Limited IPO Lead Manager(s):
Beeline Capital Advisors Pvt Ltd
Company Contact Information:
Remus Pharmaceuticals Limited
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli bopal Road, Ahmedabad - 380054
